Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
Blood
; 143(20): 2029-2036, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394666
3.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Blood
; 141(11): 1308-1315, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375118
4.
Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.
Rheumatology (Oxford)
; 63(3): 787-790, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37540112
5.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Blood
; 139(17): 2666-2672, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35171994
6.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood
; 139(18): 2747-2757, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511184
7.
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Future Oncol
; 20(14): 935-950, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197267
8.
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Br J Haematol
; 201(6): 1103-1115, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974007
9.
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.
Blood
; 138(25): 2686-2695, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34479366
10.
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood
; 137(9): 1192-1195, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080624
11.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica
; 108(10): 2774-2782, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078253
12.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212642
13.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141632
14.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
15.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
16.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
17.
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Br J Haematol
; 194(1): 120-131, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036560
18.
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Br J Haematol
; 192(5): 869-878, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216361
19.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol
; 21(2): 207-221, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859245
20.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419